INT-1B3 is under clinical development by InteRNA Technologies and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData, Phase I drugs for Non-Small Cell Lung Cancer have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how INT-1B3’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
INT-1B3 is under development for the treatment of melanoma, prostate cancer, triple negative breast cancer, lymphoma, hepatocellular carcinoma, colon cancer, pancreatic cancer, kidney cancer and non-small cell lung cancer. The therapeutic candidate is a miRNA based therapeutic. It targets MCL1, CCND1 and KRAS in addition it targets ENTPD1 (CD39), TIM-3, c-KIT and NT5E (CD73). It is developed based on miRNA identification and validation platform. The therapeutic candidate is a lipid based nano-particle formulation. It is administered through intravenous route.
InteRNA Technologies overview
InteRNA Technologies (InteRNA) is a biotechnology company that develops microRNA (miRNA) based drugs for the treatment of cancer. Its product pipeline includes INT-1B3, INT-5A2, INT- 1G8, INT -6c4/5c4, INT-2H10 and INT-2F7/1C4. The company is investigating its lead candidate, INT-1B3, a LNP-formulated, chemically modified miRNA mimic for the treatment of hepatocellular carcinoma (HCC). It also employs miRNA discovery and functional validation platform for evaluating its pipeline candidates for back-up candidates for HCC and for the treatment of HCC, renal cell cancer, pancreatic and prostate cancer, head and neck cancer, melanoma and non-small cell lung cancer. The company secures funding from INKEF capital, Aglaia Biomedical Ventures, Oost NL, Waterman 40 Holding, and Biox Biosciences. InteRNA is headquartered in Nijmegen, Gelderland, the Netherlands.
For a complete picture of INT-1B3’s drug-specific PTSR and LoA scores, buy the report here.